It was found that CRC cells downregulated the expression of GPR84 in BMM to promote osteoclastogenesis in an IL-11-dependent manner, and therefore, GPR84 may be a potential therapeutic target to attenuate CRC metastasis-induced bone destruction [108] (Figure 2). The gene discussed is IL11; the disease is colorectal carcinoma.